Institut Català de la Salut
[Santangelo A, Striano P] Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy. Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy. [Chelleri C, Pasquinucci M, Cappozzo F] Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy. [Tomasino M] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-06-17T08:28:59Z
2025-06-17T08:28:59Z
2025-05
Café-au-lait macules; Early diagnosis; Neurofibromatosis
Máculas café con leche; Diagnóstico precoz; Neurofibromatosis
Màcules cafè amb llet; Diagnòstic precoç; Neurofibromatosi
Background: Neurofibromatosis type 1 (NF1) is a rare multisystem disorder characterized by variable expressivity and increased tumor risk. Café-au-lait macules (CALMs) are a hallmark of the disease, often representing one of the earliest clinical manifestations and allowing a clinical NF1 diagnosis if six or more are present. In this study, we aimed to investigate the prognostic value of CALMs at birth in NF1 patients. Methods: We conducted a retrospective study in patients aged ≥ 4 years presenting with CALMs at our Institution between 2020 and 2021, with a minimum follow-up of four years. We retrospectively collected data on CALMs at birth and other clinical manifestations associated with NF1. Results: Among 208 patients evaluated, including 147 with a confirmed diagnosis of NF1, 110 did not show CALMs at birth, and 98 had at least one. The absence of CALMs at birth did not correlate with a lower likelihood of NF1. In contrast, the CALM number at birth directly correlated with the likelihood of NF1, up to 95% in patients with ≥5 macules. Additionally, a higher number of CALMs correlated with a greater prevalence of plexiform neurofibromas (p < 0.001). Conclusions: Our findings suggest that a higher number of CALMs may indicate a more severe form of NF1, with an increased risk of plexiform neurofibromas. These results emphasize the importance of a comprehensive evaluation of patients with CALMs, especially in case of multiple lesions, aiming at implementing early NF1 diagnosis, follow-up strategies, and overall patient management.
This research was supported by PNRR-MUR-M4C2 PE0000006 Research Program “MNESYS”—A multiscale integrated approach to the study of the nervous system in health and disease.
Article
Published version
English
Marcadors bioquímics; Neurofibromatosi - Diagnòstic; Trastorns de la pigmentació; Neurofibromatosi - Aspectes genètics; DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Nerve Tissue::Nerve Sheath Neoplasms::Neurofibroma::Neurofibromatoses::Neurofibromatosis 1; DISEASES::Neoplasms::Neoplasms::Neoplastic Syndromes, Hereditary::Neurofibromatoses::Neurofibromatosis 1; Other subheadings::Other subheadings::Other subheadings::/genetics; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Early Diagnosis; CHEMICALS AND DRUGS::Biological Factors::Biomarkers; ENFERMEDADES::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::trastornos de la pigmentación::manchas café con leche; ENFERMEDADES::neoplasias::neoplasias::síndromes neoplásicos hereditarios::neurofibromatosis::neurofibromatosis 1; Otros calificadores::Otros calificadores::Otros calificadores::/genética; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico precoz; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
MDPI
Cancers;17(9)
https://doi.org/10.3390/cancers17091490
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]